WallStSmart

Danaher Corporation (DHR)vsLaboratory Corporation of America Holdings (LH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 76% more annual revenue ($24.57B vs $13.95B). DHR leads profitability with a 14.7% profit margin vs 6.3%. LH appears more attractively valued with a PEG of 1.10. LH earns a higher WallStSmart Score of 63/100 (C+).

DHR

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.3
Piotroski: 4/9Altman Z: 2.36

LH

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 5.5Value: 8.7Quality: 7.0
Piotroski: 4/9Altman Z: 2.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DHRSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$135.07

Current Price

$187.15

$52.08 premium

UndervaluedFair: $135.07Overvalued
LHUndervalued (+13.2%)

Margin of Safety

+13.2%

Fair Value

$333.88

Current Price

$266.02

$67.86 discount

UndervaluedFair: $333.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DHR4 strengths · Avg: 8.3/10
Market CapQuality
$134.43B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Free Cash FlowQuality
$1.75B8/10

Generating 1.7B in free cash flow

LH1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

DHR3 concerns · Avg: 3.7/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

LH2 concerns · Avg: 3.5/10
P/E RatioValuation
25.4x4/10

Moderate valuation

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DHR

The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bull Case : LH

The strongest argument for LH centers on Price/Book. PEG of 1.10 suggests the stock is reasonably priced for its growth.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : LH

The primary concerns for LH are P/E Ratio, Profit Margin.

Key Dynamics to Monitor

LH carries more volatility with a beta of 0.97 — expect wider price swings.

LH is growing revenue faster at 5.6% — sustainability is the question.

DHR generates stronger free cash flow (1.7B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

LH scores higher overall (63/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Laboratory Corporation of America Holdings

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.

Visit Website →

Want to dig deeper into these stocks?